Prognostic Impact of Copy Number Alterations’ Profile and AID/RAG Signatures in Acute Lymphoblastic Leukemia (ALL) with BCR::ABL and without Recurrent Genetic Aberrations (NEG ALL) Treated with Intensive ChemotherapyMarta Libura, W Wiktor-Jędrzejczak, Lidia Gil et al.|Cancers|2023Cited by 3
A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized studyAgnieszka Wierzbowska, Gail J. Roboz, Anna Czyż et al.|Blood|2025Cited by 1
A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)Agnieszka Wierzbowska, Gail J. Roboz, Anna Czyż et al.|Blood|2022Cited by 0
Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 StudyAgnieszka Wierzbowska, Gail J. Roboz, Agnieszka Pluta et al.|Blood|2022Cited by 0
P491: DAY 14 MEASURABLE RESIDUAL DISEASE ASSESSMENT PREDICTS TREATMENT OUTCOMES IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY - RESULTS OF THE PALG-AML1/2016 STUDYAgnieszka Wierzbowska, Gail J. Roboz, Agnieszka Pluta et al.|HemaSphere|2023Cited by 0